Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 5/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147464 | 0.89 | PDE3B (0.48) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL21004583 | 0.89 | PDE3B (0.48) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL8130922 | 0.83 | EPHX2 (0.46) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL8253938 | 0.81 | PDE3B (0.44) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL23708521 | 0.80 | PDE3B (0.55) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL13162608 | 0.80 | PDE3B (0.55) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL20069121 | 0.80 | PDE3B (0.55) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL2743227 | 0.78 | PDE3B (0.50) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL20147430 | 0.76 | HRH3 (0.52) | PDE3BPDE3APDE10AKDM5ARIPK1 | |
| SCHEMBL6123517 | 0.76 | KDM5A (0.60) | PDE3BPDE3APDE10AKDM5ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | PDE3B 1631/4885PDE3A 1381/4885PDE10A 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.